AstroStem Alzheimer's Treatment
Do you or someone you love suffer from memory loss, possibly due to Alzheimer’s Disease, and do you take an Alzheimer’s medication? Unfortunately, medications may slow the progression of Alzheimer’s but there is no current treatment to fully cure or prevent the progression of this dementia.
New research, however, is looking into the possibility that stem cells, which have been shown to regenerate nerve cells, may reverse the cognitive decline in Alzheimer’s disease. Valden Medical, a Honolulu-based clinical research site, led by Principal Investigator Denis Mee-Lee, MD, has been designated as one of only three US research centers to conduct an FDA approved, ground-breaking study.
The study seeks men and women, age 50 or above for a free memory and medical evaluation to determine if they qualify to participate in this study. If suitable, a little fatty tissue will be removed by liposuction from the person’s abdomen. Then his or her own (autologous) stem cells will be isolated from this tissue and carefully re-infused into a vein every two weeks for ten visits. Careful monitoring, including frequent memory and medical assessments, and interviews with a family member or caregiver, will be conducted throughout the study. A stipend will be provided to both subject and the caregiver for time and travel expended.
To see if you or your loved one would qualify for this study, please Click Here to complete the PreScreen form and someone will contact you shortly after receiving your submission.
or Call 808-538-2800 or email us at email@example.com for more information.
Re-kinect Tardive Dyskinesia Study
Tardive Dyskinesia (TD) is a movement disorder characterized by involuntary movements of various areas of the body, including but not limited to the tongue, lips, face, trunk and extremities. TD is an area of major unmet medical need, given the current lack of treatments.
This is a prospective study that aims to quantify the prevalence of possible TD in outpatient psychiatric patients in the United States (US), as well as to describe the associated disease burden in a cohort of patients with one or more psychiatric disorders and a cumulative lifetime exposure to antipsychotic medication of three months of more. Each patient will be examined by a psychiatrist and will answer several questionnaires about how their TD symptoms and their quality of life. The overall aim of the study is to evaluate the unmet need and the impact of involuntary movements in a real-word cohort of patients.
Call 808-538-2800 or email us at firstname.lastname@example.org for more information.
KINECT 3 is an ongoing, randomized, parallel, double-blind multinational Phase 3 trial comparing NBI-98854/valbenzine to placebo in patients with Moderate-Severe Tardive Dyskinesia. The study is a randomized, parallel-group, double-blind, placebo-controlled, Phase III clinical trial utilizing the capsule formulation of NBI-98854 in moderate to severe tardive dyskinesia patients with underlying schizophrenia, schizoaffective disorder or mood disorder (including bipolar disorder or major depressive disorder). The primary endpoint in the Kinect 3 study will be the mean change from baseline in the Abnormal Involuntary Movement Scale (AIMS) as assessed by blinded central raters. The Kinect 3 study will include approximately 240 subjects randomized to either placebo, once daily 40mg of NBI-98854 or once daily 80mg of NBI-98854 for six weeks. Subsequent to the completion of the six week placebo-controlled dosing, all subjects will continue on once daily 40mg or once daily 80mg of NBI-98854 through Week 48. For more info go to: https://www.kinect3study.com/
We invite those 18 to 85 years old who are experiencing involuntary movements in their face or other parts of their body – and suffer from bipolar disorder, mood disorder, schizoaffective disorder, or schizophrenia – to see if they may qualify for the Kinect 4 Study.
The purpose of this clinical research study is to evaluate the safety and tolerability of an investigational oral medication for tardive dyskinesia. Each individual will be evaluated to determine his or her eligibility. Those who qualify will receive study medication, study-related medical exams, and lab tests at no charge. Compensation for time and travel may also be available.
Participants will be screened for eligibility and, if deemed eligible, will receive the medication for the study treatment period of 48 weeks (which includes 14 in-office visits and a follow-up appointment four weeks after completing study treatment). Throughout the study, participants will continue to receive regular general health check-ups and monitoring of TD symptoms.
For more info go to: https://www.kinect4study.com/
T-Force Gold Treatment for Tourette's Syndrome
We invite boys and girls aged 6 to 17 who have Tourette syndrome to see if they may qualify
for the T-Force Gold Study. The primary purpose of this research study is to determine the
effectiveness, safety, and tolerability of an investigational medication for Tourette syndrome.
Each child who qualifies will receive study medication, study-related medical exams, and
study-related laboratory tests at no cost.
To learn more, and to see if your child may qualify, visit TForceGoldStudy.com or call Valden Medical at (808) 538-2800.